Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Amazon Taking on AT&T and Verizon? Why It’s Unlikely.
Elon Musk says Twitter in transition to ‘everything app’ X will ‘only have dark mode’
EY Announces Clearfield’s Cheri Beranek as an Entrepreneur Of The Year® 2023 Heartland Award Winner
Bitcoin Mining Revenue Gauge Nears Record Low as Prices Stagnate
GM's Cruise cancels its employee equity program in Q4
Nasa reveals the most colourful picture of the universe ever made
Mysterious fairy circles are increasing across the world and scientists are baffled
Get $500 off this Intel Evo HP Spectre touchscreen laptop